Paxlovid
Long COVID-19
Kanecia Obie ZimmermanUNKNOWNPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
31 Active assets in the Long COVID-19 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Immulina Tm University of Mississippi Medical Center | Phase 3 | BB |
Ivabradine Kanecia Obie Zimmerman | Phase 2 | B |
Sirolimus Icahn School of Medicine at Mount Sinai | Phase 3 | B |
Solriamfetol Duke University | Phase 2 | B |
NORVIR Kanecia Obie Zimmerman | Phase 2 | B |
View all 31 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →